William Vandergrift to Glioblastoma
This is a "connection" page, showing publications William Vandergrift has written about Glioblastoma.
Connection Strength
0.856
-
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.
Score: 0.142
-
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.
Score: 0.141
-
Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 12; 82(6):945-952.
Score: 0.124
-
RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016 Jun; 37(6):7525-34.
Score: 0.103
-
Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015 Feb; 35(2):615-25.
Score: 0.097
-
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013 Aug; 114(1):43-50.
Score: 0.086
-
Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab Brain Dis. 2013 Sep; 28(3):355-66.
Score: 0.085
-
Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012 Jun; 37(6):1192-200.
Score: 0.078